Lack Of Globally Accepted Definition of “Counterfeit Drug” Hurts U.S. FDA, Department Of Commerce Drive To Tackle Problem
This article was originally published in PharmAsia News
Executive Summary
Efforts by global stakeholders - including national governments, nongovernmental organizations, and drug companies - to curtail counterfeit drug production are hampered by the lack of an agreed-upon definition for "counterfeit.
You may also be interested in...
U.S. FDA Suggests Multi-layered Approach To Combat Counterfeit Drugs
SEOUL - U.S. FDA is encouraging regulatory counterparts in Asia Pacific Economic Cooperation forum countries to adopt a multi-layered approach to combat counterfeit drugs
U.S. FDA Suggests Multi-layered Approach To Combat Counterfeit Drugs
SEOUL - U.S. FDA is encouraging regulatory counterparts in Asia Pacific Economic Cooperation forum countries to adopt a multi-layered approach to combat counterfeit drugs
Chinese Distributor Of Counterfeit Pharmaceuticals Sentenced To Prison For 78 Months, $1.286 Million In Restitution To Pfizer And Lilly
SHANGHAI - The 5th Circuit U.S. Court of Appeals re-sentenced Kevin Xu, owner of Pacific Orient International, a pharmaceutical distributor in China, to prison for conspiring to distribute counterfeit and misbranded drugs, United States Attorney José Angel Moreno announced April 23